首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Thromboembolism in lung cancer - An area of urgent unmet need
【24h】

Thromboembolism in lung cancer - An area of urgent unmet need

机译:肺癌中的血栓栓塞症-亟待解决的领域

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: Thromboembolism is common in lung cancer. Current thromboprophylaxis guidelines lack specific recommendations for appropriate strategies in this high thrombotic risk patient cohort. We profiled lung cancer patients receiving anti-cancer therapy. Thromboembolism incidence and thromboembolism-related mortality rates are reported and we explored patient, disease, and treatment-related risk factors associated with higher thrombotic rates. Methods: Retrospective review of lung cancer patients referred to a Comprehensive Cancer Centre between 01/07/2011 and 30/06/2012 for anti-cancer therapy. Data were collected from medical, pharmacy, pathology and diagnostic imaging electronic records. Results: After a median follow up of 10 months (range: 0.03-32 months), 24/222 patients (10.8%) had developed radiologically confirmed thromboembolism; 131 events per 1000 person-years (95%CI 87-195). Thromboembolism occurred equally in patients with non-small cell and small cell lung cancer (10.8% and 10.5% respectively), and more frequently among patients with adenocarcinoma compared to squamous cell carcinoma (14.7% and 5.3% respectively). Chemotherapy-treated patients experienced thromboembolism more often than patients who did not receive chemotherapy (HR 5.7 95%CI 2.2-14.8). Radiotherapy was also associated with more frequent thromboembolism (HR 5.2 95%CI 2.0-13.2). New lung cancer diagnosis, presence of metastatic disease, second primary malignancy and Charlson Index ≥5 were also associated with higher rates of thromboembolism. Importantly, pharmacological thromboprophylaxis (P-TP) was not routinely or systematically prescribed for ambulant lung cancer patients during any treatment phase, at this institution. The majority (83%) of thromboembolic events occurred in the ambulatory care setting. Conclusion: Morbidity and mortality from thromboembolism occurs frequently in lung cancer. Thromboprophylaxis guidelines should be developed for the ambulatory care setting.
机译:简介:血栓栓塞在肺癌中很常见。当前的血栓预防指南缺乏针对这种高血栓风险患者的适当策略的具体建议。我们介绍了接受抗癌治疗的肺癌患者。报告了血栓栓塞的发生率和与血栓栓塞有关的死亡率,我们探讨了与较高的血栓栓塞率相关的患者,疾病和与治疗有关的危险因素。方法:2011年1月7日至2012年6月30日之间对肺癌患者的回顾性研究转介至综合癌症中心进行抗癌治疗。数据是从医学,药学,病理学和诊断成像电子记录中收集的。结果:中位随访10个月(范围:0.03-32个月)后,有24/222例患者(10.8%)发生了放射学证实的血栓栓塞;每1000人年131个事件(95%CI 87-195)。非小细胞肺癌和小细胞肺癌患者血栓栓塞的发生率相同(分别为10.8%和10.5%),与鳞状细胞癌相比,腺癌患者的血栓栓塞发生率更高(分别为14.7%和5.3%)。与未接受化疗的患者相比,接受化学疗法治疗的患者发生血栓栓塞的频率更高(HR 5.7 95%CI 2.2-14.8)。放疗还与更频繁的血栓栓塞相关(HR 5.2 95%CI 2.0-13.2)。新的肺癌诊断,转移性疾病的存在,第二原发恶性肿瘤和Charlson指数≥5也与血栓栓塞发生率增高相关。重要的是,在该机构中,未在任何治疗阶段对流动性肺癌患者进行常规或系统性的药理性血栓预防(P-TP)处方。大部分(83%)血栓栓塞事件发生在门诊护理环境中。结论:血栓栓塞的发病率和死亡率在肺癌中经常发生。应为门诊护理环境制定预防血栓的指南。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号